Should I buy or sell ImmunoGen stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks .

What is ImmunoGen's stock price target for 2024?

12 analysts have issued 1 year price objectives for ImmunoGen's stock. Their IMGN share price targets range from $16.00 to $31.26. On average, they predict the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 17.5%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts .

How have IMGN shares performed in 2024?

ImmunoGen's stock was trading at $29.65 at the beginning of the year. Since then, IMGN shares have increased by 5.3% and is now trading at $31.23. View the best growth stocks for 2024 here .

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.14. The biotechnology company had revenue of $83.20 million for the quarter, compared to analysts' expectations of $49.15 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. The firm's revenue was up 485.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.24) earnings per share.

What ETFs hold ImmunoGen's stock?

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) , Principal Healthcare Innovators ETF (BTEC) , Invesco DWA SmallCap Momentum ETF (DWAS) , iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ) . ProShares Ultra Nasdaq Biotechnology (BIB) .

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com . Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE) , NVIDIA (NVDA) , Micron Technology (MU) , Immunomedics (IMMU) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Gilead Sciences (GILD) , OPKO Health (OPK) , AT&T (T) and Dynavax Technologies (DVAX) .

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. Read More

NASDAQ:IMGN

ImmunoGen (IMGN) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free IMGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $31.23
▼
$31.23
50-Day Range: $31.23
▼
$31.23
52-Week Range: $3.61
▼
$31.25

Volume: 40 shs
Average Volume: 8.78 million shs
Market Capitalization: $8.32 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.77

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media Sustainability

Get ImmunoGen alerts:

ImmunoGen MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 17.5% Downside
$25.77 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 362.50%
From $0.08 to $0.37 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.66 out of 5 stars

Medical Sector

778th out of 914 stocks

Biotechnology Industry

14th out of 24 stocks

1.1

Analyst's Opinion

Consensus Rating
ImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.
Amount of Analyst Coverage
ImmunoGen has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for IMGN.

0.0

Dividend Strength

Dividend Yield
ImmunoGen does not currently pay a dividend.
Dividend Growth
ImmunoGen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ImmunoGen has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for ImmunoGen is -0.78.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for ImmunoGen this week, compared to 5 articles on an average week.
Search Interest
Only 1 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmunoGen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.07% of the stock of ImmunoGen is held by insiders.
Percentage Held by Institutions
90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About ImmunoGen Stock (NASDAQ:IMGN)

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Get your free information kit NOW, before it's too late.

IMGN Stock News Headlines

April 18, 2024 | americanbankingnews.com

ImmunoGen (NASDAQ:IMGN) Coverage Initiated by Analysts at StockNews.com

April 17, 2024 | americanbankingnews.com

ImmunoGen, Inc. (NASDAQ:IMGN) Receives Consensus Recommendation of "Hold" from Analysts

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 10, 2024 | americanbankingnews.com

ImmunoGen (NASDAQ:IMGN) Coverage Initiated at StockNews.com

March 22, 2024 | marketwatch.com

AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal

February 21, 2024 | msn.com

AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals

February 19, 2024 | ca.finance.yahoo.com

CERE Aug 2024 30.000 call

February 12, 2024 | markets.businessinsider.com

Barclays Keeps Their Hold Rating on ImmunoGen (IMGN)

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

February 12, 2024 | msn.com

AbbVie revises Q1 earnings outlook as ImmunoGen deal closes

February 9, 2024 | finance.yahoo.com

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

February 9, 2024 | seekingalpha.com

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

February 9, 2024 | msn.com

ImmunoGen Set to Merge with AbbVie, Awaiting Final Approval

February 9, 2024 | finance.yahoo.com

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

February 2, 2024 | finance.yahoo.com

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2024 | finance.yahoo.com

ImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo Finance

January 9, 2024 | finance.yahoo.com

How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry

January 4, 2024 | nasdaq.com

IMGN Quantitative Stock Analysis

January 4, 2024 | msn.com

All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy

December 27, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY

December 22, 2023 | finance.yahoo.com

Are Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?

December 19, 2023 | morningstar.com

Immunogen Inc IMGN

December 16, 2023 | msn.com

Immunogen (IMGN) Price Target Increased by 35.04% to 31.68

December 7, 2023 | reuters.com

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

December 7, 2023 | finance.yahoo.com

AbbVie acquiring Cerevel Therapeutics in $8.7B deal

December 5, 2023 | msn.com

ImmunoGen bags priority review for full approval of ovarian cancer drug

December 5, 2023 | markets.businessinsider.com

ImmunoGen Receives FDA's Priority Review For ELAHERE In Platinum-Resistant Ovarian Cancer

See More Headlines

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/31/2023
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:IMGN
CUSIP: 45253H10
CIK: 855654
Web: www.immunogen.com
Phone: (781) 895-0600
Fax: 781-895-0611
Employees: 277
Year Founded: 1981

Price Target and Rating

Average Stock Price Target: $25.77
High Stock Price Target: $31.26
Low Stock Price Target: $16.00
Potential Upside/Downside: -17.5%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 390.38
P/E Growth: N/A
Net Income: $-222,930,000.00
Net Margins: -25.56%
Pretax Margin: -25.24%
Return on Equity: -22.11%
Return on Assets: -13.53%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 5.70
Quick Ratio: 5.65

Sales & Book Value

Annual Sales: $287.61 million
Price / Sales: 28.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 43.99

Miscellaneous

Outstanding Shares: 266,264,000
Free Float: 252,764,000
Market Cap: $8.32 billion
Optionable: Optionable
Beta: 1.18

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Mark Joseph Enyedy (Age 60)
President, CEO & Director
Comp: $1.28M
Dr. Michael J. Vasconcelles M.D. (Age 61)
Ph.D., Chief Medical Officer
Comp: $304.62k
Ms. Lauren A. White M.B.A. (Age 45)
Senior VP & Chief Financial Officer
Anabel Chan
Head of Investor Relations
Mr. Daniel S. Char J.D. (Age 62)
Senior VP, Chief Legal Officer & Secretary
Ms. Courtney O'Konek
Senior Director of Corporate Communications & Investor Relations
Ms. Audrey Bergan
Senior VP & Chief HR Officer
Dr. Theresa G. Wingrove (Age 66)
Senior Vice President of Regulatory Affairs & Quality
Comp: $548.21k
Ms. Isabel Kalofonos
Senior VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares.
View IMGN analyst ratings or view top-rated stocks.
What is ImmunoGen's stock price target for 2024?: 12 analysts have issued 1 year price objectives for ImmunoGen's stock. Their IMGN share price targets range from $16.00 to $31.26. On average, they predict the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 17.5%.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.
How have IMGN shares performed in 2024?: ImmunoGen's stock was trading at $29.65 at the beginning of the year. Since then, IMGN shares have increased by 5.3% and is now trading at $31.23.
View the best growth stocks for 2024 here.
How were ImmunoGen's earnings last quarter?: ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.14. The biotechnology company had revenue of $83.20 million for the quarter, compared to analysts' expectations of $49.15 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. The firm's revenue was up 485.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.24) earnings per share.
What ETFs hold ImmunoGen's stock?: ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Principal Healthcare Innovators ETF (BTEC), Invesco DWA SmallCap Momentum ETF (DWAS), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?: 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.
What other stocks do shareholders of ImmunoGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).
How do I buy shares of ImmunoGen?: Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does ImmunoGen have any subsidiaries?: The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More

This page (NASDAQ:IMGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ImmunoGen (IMGN) Stock Price, News & Analysis

ImmunoGen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ImmunoGen Stock (NASDAQ:IMGN)

IMGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

IMGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™